iCoat Medical AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys
Phase 2
Not yet recruiting
- Conditions
- Ischemia-reperfusion InjuryKidney Transplant; Complications
- Interventions
- Drug: iCM012 solution 2 mg/mLDrug: Placebo
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- iCoat Medical AB
- Target Recruit Count
- 200
- Registration Number
- NCT06582485
FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation
Phase 1
Completed
- Conditions
- Kidney Transplant; ComplicationsIschemia-reperfusion Injury
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- iCoat Medical AB
- Target Recruit Count
- 18
- Registration Number
- NCT05246618
- Locations
- 🇸🇪
Skane University Hospital, Malmö, Sweden
News
No news found